Rekombinanter SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N) (AA 1-419) Antikörper (Fc Tag)
Kurzübersicht für Rekombinanter SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N) (AA 1-419) Antikörper (Fc Tag) (ABIN6952664)
Target
Alle SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N) Antikörper anzeigenAntikörpertyp
Fragment
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 1-419
-
Verwendungszweck
- N Recombinant Monoclonal Antibody
-
Spezifität
- Mouse scFv fusion with human IgG1 Fc
-
Produktmerkmale
- Recombinant anti-SARS-CoV-2 Nucleoprotein Mouse ScFv is expressed from 293 cells (HEK293) with a human IgG1 Fc tag on C-terminal.
-
Aufreinigung
- Affinity-chromatography
-
Immunogen
- Recombinant Human Novel Coronavirus Nucleoprotein (N) (1-419aa) (CSB-EP3325GMY)
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- ELISA:1:10000-1:50000, WB:1:500-1:5000, GICA:1:1000-1:10000
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4 -
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C,-80 °C
-
Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
-
-
: "Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell®. ..." in: Vaccines, Vol. 11, Issue 4, (2023) (PubMed).
-
: "Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell®. ..." in: Vaccines, Vol. 11, Issue 4, (2023) (PubMed).
-
- SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N)
-
Andere Bezeichnung
- SARS-CoV-2 (SARS-CoV-2/ 2019-nCoV) N
-
UniProt
- P0DTC9
Target
-